Thomas Hvidkjær Lisle, Postdoctoral Researcher at Aarhus University, shared a post on LinkedIn:
“Time to celebrate!
I am proud to share that the final project from my PhD thesis has been published as a short-form paper in Signal Transduction and Targeted Therapy!
This project holds a special place in my heart, as it was the very first project I worked on when I joined CCIT-DK – National Center for Cancer Immune Therapy of Denmark as a M.Sc. student in 2020.
After many experiments and years of work, we can now report the successful generation of TCR-T cells recognizing a PD-L1-derived antigen.
Importantly, these PD-L1-specific TCR-T cells can recognize both tumor cells and immune cells expressing PD-L1, potentially enabling a broader attack on the immunosuppressive tumor microenvironment.
A heartfelt thank you to my co-first author, Emilie Bülow Jacobsen, and to Mads Hald Andersen for the excellent collaboration throughout this project. I am also grateful to all co-authors and collaborators who contributed to this work, particularly Rasmus O. Bak and his team for their valuable insights into CRISPR-based gene editing.
Finally, we thank the organizations that supported this research, particularly Kræftens Bekæmpelse (Danish Cancer Society), the Independent Research Fund Denmark, and the Novo Nordisk Foundation.”
Title: Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells
Authors: Thomas Landkildehus Lisle, Emilie Bülow Jacobsen, Shamaila Munir Ahmad, Özcan Met, Rasmus O. Bak, Mads Hald Andersen.
Other articles about CCIT-DK on OncoDaily.